Cardiovascular Risk Assessment and Management Making a Difference

Size: px
Start display at page:

Download "Cardiovascular Risk Assessment and Management Making a Difference"

Transcription

1 Cardiovascular Risk Assessment and Management Making a Difference Norman Sharpe March 2014

2

3 Numbers and age-standardised mortality rates from all causes, by sex, Death rates halved Life expectancy increased

4 Numbers and age-standardised mortality rates from ischaemic heart disease, by sex, Heart disease death rates reduced by more than two-thirds since 1968

5 Age-standardised mortality rates for the five major causes of mortality, Cancer and heart disease crossover late 1980s

6

7

8

9 Specific conditions contributing > 1% of total DALYs Males 2006

10 Specific conditions contributing > 1% of total DALYs Females 2006

11 Attributable burden (% of DALYs) for selected risk factors, 2006

12 Projections in health loss attributable to tobacco and high BMI, total population, 2006 to 2016 Obesity exceeds tobacco for health loss beyond 2015

13 Leading specific causes of absolute inequality between Māori and non-māori, 2006

14 Primary Care The Keystone to Heart Health Improvement

15 Why bother about CVD in primary care? In a population of 10,000 primary care patients, every year there are about: 10 coronary & stroke deaths 1 diabetic death 1 breast cancer death 1 prostate cancer death 1 suicide every year 1 road traffic death (1 cervical cancer death every 5 years)

16 EVIDENCE-BASED BEST PRACTICE GUIDELINE Cardiovascular Risk Assessment and Management Guideline December 2003

17 CV Risk Guideline 2003 What was new --- Integrated previous advice on smoking, BP, lipids and diabetes into one assessment Required bloods (lipids and fasting glucose) Recommended screening of specific age groups Recommended all treatment decisions be based on absolute cardiovascular risk - CHD and stroke risk combined Recommended intervention for individuals with CV risk above 15% 5 year level as practical and cost effective

18 Assessment of absolute CV risk What to measure and record Age and sex Ethnicity Smoking history Family history Lipid profile and fasting glucose Average of two sitting BPs BMI and waist circumference Assessment of absolute risk is the starting point for discussion

19 What does a Risk Assessment Involve? Weight Blood Pressure Smoking Diabetes Gender Family History Age Cholesterol Levels Ethnicity

20 20

21 APCSC: blood pressure, cholesterol and body mass index and the risk of coronary heart disease Blood pressure Cholesterol Body mass index Hypertension Hypercholesterolaemia 1.0 Obesity Systolic blood pressure (mmhg) Total cholesterol (mmol/l) Body mass index (kg/m 2 ) 0.5

22 Hazard ratio & 95% CI APCSC: glucose and the risks of stroke, CHD, CV death ,257 participants and 1.2M person years of follow up Total stroke 4.0 Total ischaemic heart disease 4.0 Cardiovascular death Diabetes Care 27: 2836, 2004 Usual fasting glucose (mmol/l) 1mmol/l reduction in UFG relates to 23% reduced risk IHD

23 5 year CVD risk (percent) Absolute risk of CVD over 5 years by systolic BP + other risk factors Reference category is a 50 year old nondiabetic, non-smoker female with total cholesterol 4 0 mmol/l and HDL 1 6 mmol/l. 44% Risks are given for SBP levels of 110, 120, 130, 140, 150, 160, 170, and 180 mm Hg 33% 24% 18% 12% <1% 3% 6% Reference TC Smoker HDL Male Diabetes 60 years 7mmol/L 1 mmol/l Jackson R. Lat 2005;365:434

24 Clinically High Risk Adjusted CVD Risk Clinical CVD or High risk diabetes Some genetic lipid disorders Treatment Intensity Consider specialist referral Urgent + intense multifactor treatment Drug intervention directed at all risk factors Drug interventions General advice Specific advice Lifestyle Intensive individual advice interventions CVD Risk goal Reduce risk Reduce 5-year CVD risk to < 15%

25

26

27

28

29 So, what is shared decision making? Informed (benefits and harms) patient preference Health professional expertise Discussion Treatment and/or behaviour change goal The patient shares: Impact of risk/condition on their life. Personal attitude to the risk Values Preference Health beliefs The health professional shares: Knowledge Experience Treatment options and possible evidence based outcomes Coulter, A., Collins, A. (2011). Making shared decision-making a reality: No decision about me, without me. The King s Fund Health foundation you tube

30

31

32

33 Making it happen: practice change Leadership Champion Change management Team approach Quality improvement Data collection and clean up Achievable goals and targets Continual practice improvement Patient Access Improved patient outcomes Meeting health target Happy staff Innovation Person and family centred care Community outreach Self Management- organisational and individual

34

35

36

Professor Norman Sharpe. Heart Foundation West Coast

Professor Norman Sharpe. Heart Foundation West Coast Professor Norman Sharpe Heart Foundation West Coast Primary Care the Keystone to Heart Health Improvement Norman Sharpe June 2013 The heart health continuum and the keystone position The culprit disease

More information

Key causes of preventable deaths in New Zealand In a population of 10,000 New Zealanders, every year there will be about:

Key causes of preventable deaths in New Zealand In a population of 10,000 New Zealanders, every year there will be about: Preventive care - Chronic Disease Management in primary care: a population perspective Rod Jackson University of Auckland New Zealand (22/11/8) Key causes of preventable deaths in New Zealand In a population

More information

HEALTH TARGETS IN PRIMARY CARE

HEALTH TARGETS IN PRIMARY CARE HEALTH TARGETS IN PRIMARY CARE MORE HEART AND DIABETES CHECKS BETTER HELP FOR SMOKERS TO QUIT Better Help for Smokers to Quit 90% of enrolled patients who smoke and are seen by General Practice, will be

More information

Current Issues in Cardiovascular Risk Management. Les Toop Norman Sharpe June 2014

Current Issues in Cardiovascular Risk Management. Les Toop Norman Sharpe June 2014 Current Issues in Cardiovascular Risk Management Les Toop Norman Sharpe June 2014 Risk assessment is just the beginning of a conversation Les Toop Department of General Practice, University of Otago, Christchurch

More information

Know Your Number Aggregate Report Single Analysis Compared to National Averages

Know Your Number Aggregate Report Single Analysis Compared to National Averages Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics

More information

Depok-Indonesia STEPS Survey 2003

Depok-Indonesia STEPS Survey 2003 The STEPS survey of chronic disease risk factors in Indonesia/Depok was carried out from February 2003 to March 2003. Indonesia/Depok carried out Step 1, Step 2 and Step 3. Socio demographic and behavioural

More information

Vascular Diseases. Overview: Selected Slides

Vascular Diseases. Overview: Selected Slides Vascular Diseases Overview: Selected Slides Total deaths and change in vascular death rates

More information

BEST PRACTICE MANAGEMENT: CARDIOVASCULAR RISKS

BEST PRACTICE MANAGEMENT: CARDIOVASCULAR RISKS BEST PRACTICE MANAGEMENT: CARDIOVASCULAR RISKS Neil R Poulter ICCH, Imperial College London BHIVA: October 10th, 2008 Background CVD is the biggest single killer in the world CVD rates are increasing High

More information

Total risk management of Cardiovascular diseases Nobuhiro Yamada

Total risk management of Cardiovascular diseases Nobuhiro Yamada Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible

More information

Cardiovascular Disease Prevention: Current Knowledge, Future Directions

Cardiovascular Disease Prevention: Current Knowledge, Future Directions Cardiovascular Disease Prevention: Current Knowledge, Future Directions Daniel Levy, MD Director, Framingham Heart Study Professor of Medicine, Boston University School of Medicine Editor-in-Chief, Journal

More information

well-targeted primary prevention of cardiovascular disease: an underused high-value intervention?

well-targeted primary prevention of cardiovascular disease: an underused high-value intervention? well-targeted primary prevention of cardiovascular disease: an underused high-value intervention? Rod Jackson University of Auckland, New Zealand October 2015 Lancet 1999; 353: 1547-57 Findings: Contribution

More information

2016 EUROPEAN GUIDELINES ON CVD PREVENTION IN CLINICAL PRACTICE

2016 EUROPEAN GUIDELINES ON CVD PREVENTION IN CLINICAL PRACTICE 2016 EUROPEAN GUIDELINES ON CVD PREVENTION IN CLINICAL PRACTICE Massimo F Piepoli, MD, PhD, FESC, Piacenza, Italy on behalf of the 6 th Joint Task Force 2 3 Guidelines still based upon the principles of

More information

The local healthcare system: Focusing on health

The local healthcare system: Focusing on health The local healthcare system: Focusing on health Sian Griffiths Professor of Public Health Director of the School of Public Health Chairman, Department of Community and Family Medicine The Chinese University

More information

(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects

(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects Table 1. Distribution of baseline characteristics across tertiles of OPG adjusted for age and sex (n=6279). Continuous variables are reported as mean with 95% confidence interval and categorical values

More information

CVD Prevention, Who to Consider

CVD Prevention, Who to Consider Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..

More information

Understanding new international guidelines to tackle CV Risk: A practical model John Deanfield, MD UCL, London United Kingdom s

Understanding new international guidelines to tackle CV Risk: A practical model John Deanfield, MD UCL, London United Kingdom s Understanding new international guidelines to tackle CV Risk: A practical model John Deanfield, MD UCL, London United Kingdom s Ho Chi Minh City, Vietnam August 7, 2014 JBS 2 Risk Guidelines (2005) Based

More information

Yuqing Zhang, M.D., FESC Department of Cardiology, Fu Wai Hospital. CAMS & PUMC, Beijing, China

Yuqing Zhang, M.D., FESC Department of Cardiology, Fu Wai Hospital. CAMS & PUMC, Beijing, China What Can We Learn from the Observational Studies and Clinical Trials of Prehypertension? Yuqing Zhang, M.D., FESC Department of Cardiology, Fu Wai Hospital. CAMS & PUMC, Beijing, China At ARIC visit 4

More information

Secondary prevention and systems approaches: Lessons from EUROASPIRE and EUROACTION

Secondary prevention and systems approaches: Lessons from EUROASPIRE and EUROACTION Secondary prevention and systems approaches: Lessons from EUROASPIRE and EUROACTION Dr Kornelia Kotseva National Heart & Lung Insitute Imperial College London, UK on behalf of all investigators participating

More information

CVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic

CVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic CVD Risk Assessment Michal Vrablík Charles University, Prague Czech Republic What is Risk? A cumulative probability of an event, usually expressed as percentage e.g.: 5 CV events in 00 pts = 5% risk This

More information

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,

More information

Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up

Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up... Study Population: 340... Total Population: 500... Time Window of Baseline: 09/01/13 to 12/20/13... Time Window of Follow-up:

More information

ASSeSSing the risk of fatal cardiovascular disease

ASSeSSing the risk of fatal cardiovascular disease ASSeSSing the risk of fatal cardiovascular disease «Systematic Cerebrovascular and coronary Risk Evaluation» think total vascular risk Assess the risk Set the targets Act to get to goal revised; aupril

More information

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD

More information

Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.

Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix to: Banks E, Crouch SR, Korda RJ, et al. Absolute risk of cardiovascular

More information

EuroPrevent 2010 Fatal versus total events in risk assessment models

EuroPrevent 2010 Fatal versus total events in risk assessment models EuroPrevent 2010 Fatal versus total events in risk assessment models Pekka Jousilahti, MD, PhD,Research Professor National Institute for Health and Welfare, Finland Risk assessment models Estimates the

More information

Is there a mechanism of interaction between hypertension and dyslipidaemia?

Is there a mechanism of interaction between hypertension and dyslipidaemia? Is there a mechanism of interaction between hypertension and dyslipidaemia? Neil R Poulter International Centre for Circulatory Health NHLI, Imperial College London Daegu, Korea April 2005 Observational

More information

Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution

Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution of A: total cholesterol (TC); B: low-density lipoprotein

More information

Should we base treatment decisions on short-term or lifetime CVD risk? Rod Jackson University of Auckland New Zealand

Should we base treatment decisions on short-term or lifetime CVD risk? Rod Jackson University of Auckland New Zealand Should we base treatment decisions on short-term or lifetime CVD risk? Rod Jackson University of Auckland New Zealand Presentation outline Strengths & weaknesses of short-term risk approach Strengths &

More information

Modelling Reduction of Coronary Heart Disease Risk among people with Diabetes

Modelling Reduction of Coronary Heart Disease Risk among people with Diabetes Modelling Reduction of Coronary Heart Disease Risk among people with Diabetes Katherine Baldock Catherine Chittleborough Patrick Phillips Anne Taylor August 2007 Acknowledgements This project was made

More information

Cheshire & Merseyside Cardiovascular Programme

Cheshire & Merseyside Cardiovascular Programme Cheshire & Merseyside Cardiovascular Programme CVD Prevention and lipids: Are we doing enough? POP-UP UNIVERSITY SESSION Date: Thursday 6 September - Time: 10:45-11:45 Dr Scott W Murray Consultant Cardiologist

More information

Andrejs Kalvelis 1, MD, PhD, Inga Stukena 2, MD, Guntis Bahs 3 MD, PhD & Aivars Lejnieks 4, MD, PhD ABSTRACT INTRODUCTION. Riga Stradins University

Andrejs Kalvelis 1, MD, PhD, Inga Stukena 2, MD, Guntis Bahs 3 MD, PhD & Aivars Lejnieks 4, MD, PhD ABSTRACT INTRODUCTION. Riga Stradins University CARDIOVASCULAR RISK FACTORS ORIGINAL ARTICLE Do We Correctly Assess the Risk of Cardiovascular Disease? Characteristics of Risk Factors for Cardiovascular Disease Depending on the Sex and Age of Patients

More information

Epidemiologic Measure of Association

Epidemiologic Measure of Association Measures of Disease Occurrence: Epidemiologic Measure of Association Basic Concepts Confidence Interval for population characteristic: Disease Exposure Present Absent Total Yes A B N 1 = A+B No C D N 2

More information

Guidelines on cardiovascular risk assessment and management

Guidelines on cardiovascular risk assessment and management European Heart Journal Supplements (2005) 7 (Supplement L), L5 L10 doi:10.1093/eurheartj/sui079 Guidelines on cardiovascular risk assessment and management David A. Wood 1,2 * 1 Cardiovascular Medicine

More information

Physical health assessment and monitoring in long-term mental health care

Physical health assessment and monitoring in long-term mental health care Physical health assessment and monitoring in long-term mental health care Dr Alan Farmer Consultant Psychiatrist Worcestershire Mental Health Partnership NHS Trust A brief questionnaire Current thoughts,

More information

MPharmProgramme. Hypertension (HTN)

MPharmProgramme. Hypertension (HTN) MPharmProgramme Hypertension (HTN) Slide 1 of 30 Overview Definition Prevalence Type Causes Diagnosis Management Patients perspective Slide 2 of 30 Definition It is not a disease! So what is it? What two

More information

Diabetes Mellitus: A Cardiovascular Disease

Diabetes Mellitus: A Cardiovascular Disease Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular

More information

Volume 2; Number 11 July 2008

Volume 2; Number 11 July 2008 Volume 2; Number 11 July 2008 CONTENTS Page 1 NICE Clinical Guideline 67: Lipid Modification (May 2008) Page 7 NICE Technology Appraisal 132: Ezetimibe for the treatment of primary (heterozygous familial

More information

ABSTRACT: 9 DOES SOY CONSUMPTION HAVE AN EFFECT ON HYPERTENSION IN LOW-INCOME RURAL SOUTH AFRICAN WOMEN?

ABSTRACT: 9 DOES SOY CONSUMPTION HAVE AN EFFECT ON HYPERTENSION IN LOW-INCOME RURAL SOUTH AFRICAN WOMEN? ABSTRACT: 9 DOES SOY CONSUMPTION HAVE AN EFFECT ON HYPERTENSION IN LOW-INCOME RURAL SOUTH AFRICAN WOMEN? W.H. OLDEWAGE-THERON & A.A. EGAL Centre of Sustainable Livelihoods, Vaal University of Technology,

More information

Getting serious about preventing cardiovascular disease

Getting serious about preventing cardiovascular disease Getting serious about preventing cardiovascular disease Southwark s Experience Professor Kevin Fenton Director of Health and Wellbeing, London Borough of Southwark February 2018 Twitter: @ProfKevinFenton

More information

Mississippi Stroke Systems of Care

Mississippi Stroke Systems of Care Stroke Initiatives Mississippi State Department of Health Cassandra Dove, Chronic Disease Bureau 19 th Annual Stroke Belt Consortium March 1, 2014 Mississippi Stroke Systems of Care Heart Disease and Stroke

More information

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE

More information

Prevenzione cardiovascolare e cambiamento degli stili di vita. Gian Franco Gensini

Prevenzione cardiovascolare e cambiamento degli stili di vita. Gian Franco Gensini Prevenzione cardiovascolare e cambiamento degli stili di vita Gian Franco Gensini Main causes of death worldwide at all ages (year:: 2005) 17.5 milion Preventing Chronic Diseases A vital investiment. WHO

More information

Population models of health impact of combination polypharmacy

Population models of health impact of combination polypharmacy Population models of health impact of combination polypharmacy Global Summit on Combination Polypharmacy for CVD, 25 th September 2012 Dr Mark Huffman Northwestern University, Chicago Charity No: 1110067

More information

Risk Factors for NCDs

Risk Factors for NCDs Risk Factors for NCDs Objectives: Define selected risk factors such as; tobacco use, diet, nutrition, physical activity, obesity, and overweight Present the epidemiology and significance of the risk factors

More information

Why are NICE guidelines and standards important and relevant to us?

Why are NICE guidelines and standards important and relevant to us? Why are NICE guidelines and standards important and relevant to us? Dr Liz England GP, Laurie Pike health centre RCGP Mental Health Clinical and Commissioning Lead SWB CCG Mental Health Lead NIHR Clinical

More information

Heart Age and Cardiovascular Risk

Heart Age and Cardiovascular Risk Heart Age and Cardiovascular Risk Mark Cobain Unilever R+D Colworth Science Park Sharnbrook Bedfordshire Europrevent, Geneva April 16 2011 Conflict of Interest Statement Employment by Unilever PLC A producer

More information

Absolute cardiovascular disease risk management

Absolute cardiovascular disease risk management Quick reference guide for health professionals Absolute cardiovascular disease risk management This quick reference guide is for use by health professionals for primary prevention of cardiovascular disease

More information

Table S1. Characteristics associated with frequency of nut consumption (full entire sample; Nn=4,416).

Table S1. Characteristics associated with frequency of nut consumption (full entire sample; Nn=4,416). Table S1. Characteristics associated with frequency of nut (full entire sample; Nn=4,416). Daily nut Nn= 212 Weekly nut Nn= 487 Monthly nut Nn= 1,276 Infrequent or never nut Nn= 2,441 Sex; n (%) men 52

More information

Corporate Health Screening

Corporate Health Screening Corporate Health Screening What should I look out for? Presented by: Dr Wee Wei Keong Director Health for Life Programme WHAT IS HEALTH SCREENING? Tests/procedures carried out to detect a condition/disease

More information

The Clinical Unmet need in the patient with Diabetes and ACS

The Clinical Unmet need in the patient with Diabetes and ACS The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge

More information

Hypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital

Hypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital Hypertension and obesity Dr Wilson Sugut Moi teaching and referral hospital No conflict of interests to declare Obesity Definition: excessive weight that may impair health BMI Categories Underweight BMI

More information

Preventive Cardiology Scientific evidence

Preventive Cardiology Scientific evidence Preventive Cardiology Scientific evidence Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College London Primary prevention

More information

Diabetes, Diet and SMI: How can we make a difference?

Diabetes, Diet and SMI: How can we make a difference? Diabetes, Diet and SMI: How can we make a difference? Dr. Adrian Heald Consultant in Endocrinology and Diabetes Leighton Hospital, Crewe and Macclesfield Research Fellow, Manchester University Relative

More information

Preventing Cardiovascular Disease Stroke Primary Prevention Guidelines. John Potter Professor Ageing & Stroke Medicine University of East Anglia

Preventing Cardiovascular Disease Stroke Primary Prevention Guidelines. John Potter Professor Ageing & Stroke Medicine University of East Anglia Preventing Cardiovascular Disease Stroke Primary Prevention Guidelines John Potter Professor Ageing & Stroke Medicine University of East Anglia Preventing Cardiovascular Disease Stroke Primary Prevention

More information

Antihypertensive Trial Design ALLHAT

Antihypertensive Trial Design ALLHAT 1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes

More information

The Metabolic Syndrome: Is It A Valid Concept? YES

The Metabolic Syndrome: Is It A Valid Concept? YES The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA

More information

Secondary analyses of HSE data and linked health outcomes - an overview of work in progress. UCL (University College London)

Secondary analyses of HSE data and linked health outcomes - an overview of work in progress. UCL (University College London) Secondary analyses of HSE data and linked health outcomes - an overview of work in progress Dr Jennifer Mindell, UCL (University College London) Linked HSE mortality data (2008) In 2008, some mortality

More information

Randomized Design of ALLHAT BP Trial

Randomized Design of ALLHAT BP Trial Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril* *Wright JT, Dunn JK, Cutler JA et al. JAMA 2005:293:1595-1608. 42,418 High-risk hypertensive

More information

What s new in cardiovascular disease risk assessment and management for primary care clinicians

What s new in cardiovascular disease risk assessment and management for primary care clinicians Cardiovascular system What s new in cardiovascular disease risk assessment and management for primary care clinicians The recently released 2018 Cardiovascular Disease Risk Assessment and Management for

More information

Identification of subjects at high risk for cardiovascular disease

Identification of subjects at high risk for cardiovascular disease Master Class in Preventive Cardiology Focus on Diabetes and Cardiovascular Disease Geneva April 14 2011 Identification of subjects at high risk for cardiovascular disease Lars Rydén Karolinska Institutet

More information

Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES

Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest

More information

Shiftwork and cardiometabolic outcomes. Dr Anil Adisesh

Shiftwork and cardiometabolic outcomes. Dr Anil Adisesh Shiftwork and cardiometabolic outcomes Dr Anil Adisesh 1 FACULTY/PRESENTER DISCLOSURE Faculty: Dr Anil Adisesh Relationships with commercial interests: - None 2 Aims 1) Participants will be able to describe

More information

The Latest Generation of Clinical

The Latest Generation of Clinical The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform

More information

Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic

Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic Supplementary Information The title of the manuscript Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic stroke Xin-Wei He 1, Wei-Ling Li 1, Cai Li

More information

Placebo-Controlled Statin Trials Prevention Of CVD in Women"

Placebo-Controlled Statin Trials Prevention Of CVD in Women MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest

More information

Hospital Authority Convention 2010 Presented by : Dr Cheng Ming Kin Medical Officer,Department of Medicine Tseung Kwan O Hospital

Hospital Authority Convention 2010 Presented by : Dr Cheng Ming Kin Medical Officer,Department of Medicine Tseung Kwan O Hospital Hospital Authority Convention 2010 Prevalence of Cardiovascular Risk Factors, the Metabolic Syndrome and the 10-year risk for Coronary Heart Disease in the Staff of Tseung Kwan O Hospital Presented by

More information

Guidelines for Integrated Management of. Cardiovascular Diseases and Diabetes. in Clinics and Ri-hospitals

Guidelines for Integrated Management of. Cardiovascular Diseases and Diabetes. in Clinics and Ri-hospitals Guidelines for Integrated Management of Cardiovascular Diseases and Diabetes in Clinics and Ri-hospitals Ministry of Public Health DPR Korea January 2013 Rationale ncommunicable diseases such as cardiovascular

More information

NHS Health Check Training for Healthy Living Centre Staff and Colleagues. June 2015 Amanda Chappell

NHS Health Check Training for Healthy Living Centre Staff and Colleagues. June 2015 Amanda Chappell NHS Health Check Training for Healthy Living Centre Staff and Colleagues. June 2015 Amanda Chappell Aim of the session 1. Increase your understanding of the cardiovascular system 2. Describe the most common

More information

NHS Health Check Training for Healthy Living Centre Staff and Colleagues. June 2015 Amanda Chappell

NHS Health Check Training for Healthy Living Centre Staff and Colleagues. June 2015 Amanda Chappell NHS Health Check Training for Healthy Living Centre Staff and Colleagues. June 2015 Amanda Chappell Aim of the session 1. Understanding of the cardiovascular system 2. Describe the most common types of

More information

SIGN 149 Risk estimation and the prevention of cardiovascular disease. Quick Reference Guide July Evidence

SIGN 149 Risk estimation and the prevention of cardiovascular disease. Quick Reference Guide July Evidence SIGN 149 Risk estimation and the prevention of cardiovascular disease Quick Reference Guide July 2017 Evidence ESTIMATING CARDIOVASCULAR RISK R Individuals with the following risk factors should be considered

More information

Coronary Heart Disease in Women Go Red for Women

Coronary Heart Disease in Women Go Red for Women Coronary Heart Disease in Women Go Red for Women Dr Fiona Stewart Green Lane Cardiovascular Service and National Women s Health Auckland City Hospital Auckland Heart Group Women are Different from Men

More information

Dr Anne King dc life dclife.co.uk

Dr Anne King dc life dclife.co.uk The Vampire Strikes Back Dr Anne King dc life dclife.co.uk Overview Clinical -v- Underwriting Blood physiology The blood sample Screening for the 3 main killers The top 3 useful blood tests The future

More information

CYNLLUN CODI CALON/UPLIFTING HEART PROJECT

CYNLLUN CODI CALON/UPLIFTING HEART PROJECT CYNLLUN CODI CALON/UPLIFTING HEART PROJECT BACKGROUND OF PROJECT Joint initiative between psychiatric services and Gwynedd local health board, funded by WAG Inequalities in Health fund. Covering the county

More information

Discussion points. The cardiometabolic connection. Cardiometabolic Risk Management in the Primary Care Setting

Discussion points. The cardiometabolic connection. Cardiometabolic Risk Management in the Primary Care Setting Session #5 Cardiometabolic Risk Management in the Primary Care Setting Sonja Reichert, MD MSc FCFP FACPM Betty Harvey, RNEC BScN MScN Amanda Mikalachki, RN BScN CDE S Discussion points Whom should we be

More information

University of Padova, Padua, Italy, and HARVEST Study Group, Italy

University of Padova, Padua, Italy, and HARVEST Study Group, Italy University of Padova, Padua, Italy, and HARVEST Study Group, Italy ISOLATED SYSTOLIC HYPERTENSION IN THE YOUNG DOES NOT IMPLY AN INCREASED RISK OF FUTURE HYPERTENSION NEEDING TREATMENT Mos L, Saladini

More information

Type 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice.

Type 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice. Type 2 Diabetes Stopping Smoking Consider referral to smoking cessation BMI > 25 kg m² Set a weight loss target of a 5-10% reduction Consider referring for weight management advice Control BP to

More information

Metabolic Syndrome and Workplace Outcome

Metabolic Syndrome and Workplace Outcome Metabolic Syndrome and Workplace Outcome Maine Worksite Wellness Initiative June 15, 2010 Alyssa B. Schultz Dee W. Edington Current Definition* of Metabolic Syndrome At least 3 of the following: Waist

More information

Metabolic Syndrome: A Preventable & Treatable Cluster of Conditions

Metabolic Syndrome: A Preventable & Treatable Cluster of Conditions Metabolic Syndrome: A Preventable & Treatable Cluster of Conditions April D. McNeill MD Candidate 2016, Southern Illinois University, School of Medicine GE-NMF Primary Care Leadership Program, July 2013

More information

Community Based Diabetes Prevention

Community Based Diabetes Prevention Community Based Diabetes Prevention Melanie Davies Professor of Diabetes Medicine Outline NIHR Programme Grant proposal and update to progress The Vascular Check programme HbA1c debate Algorithm to detect

More information

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered

More information

Dyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram

Dyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram Dyslipidaemia Is there any new information? Dr. A.R.M. Saifuddin Ekram PhD,FACP,FCPS(Medicine) Professor(c.c.) & Head Department of Medicine Rajshahi Medical College Rajshahi-6000 New features of ATP III

More information

Physical Health Checks

Physical Health Checks Improving the Quality of Physical Health Checks Kate Dale, Mental/Physical Health Project Lead BDCT Kate Beedle, Data Quality Specialist, West & South Yorkshire & Bassetlaw Commissioning Support Unit NB

More information

22. Cardiovascular disease

22. Cardiovascular disease 22. Cardiovascular disease What is cardiovascular disease (CVD)? What conditions does the term CVD include? What is the aetiology of CVD? What are the risk factors for CVD? How do you assess the absolute

More information

Biases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University

Biases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Biases in clinical research Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Learning objectives Describe the threats to causal inferences in clinical studies Understand the role of

More information

Risk Factors for Heart Disease

Risk Factors for Heart Disease Risk Factors for Heart Disease Risk Factors we cannot change (Age, Gender, Family History) Risk Factors we can change (modifiable) Smoking Blood pressure Cholesterol Diabetes Inactivity Overweight Stress

More information

Rick Fox M.A Health and Wellness Specialist

Rick Fox M.A Health and Wellness Specialist Metabolic Diseases Rick Fox M.A Health and Wellness Specialist Metabolic Diseases Metabolism is the process your body uses to get or make energy from the food you eat. Food is made up of proteins, carbohydrates

More information

Socioeconomic status and the 25x25 risk factors as determinants of premature mortality: a multicohort study of 1.7 million men and women

Socioeconomic status and the 25x25 risk factors as determinants of premature mortality: a multicohort study of 1.7 million men and women Socioeconomic status and the 25x25 risk factors as determinants of premature mortality: a multicohort study of 1.7 million men and women (Lancet. 2017 Mar 25;389(10075):1229-1237) 1 Silvia STRINGHINI Senior

More information

Supplemental Table 1. Study design and participant characteristics.

Supplemental Table 1. Study design and participant characteristics. Supplemental Table 1. Study design and participant characteristics. Study ID Study Design; Total No. of Participants Mean age at Parity Participant Selection Criteria Country; Year (PE/no PE) Index Pregnancy

More information

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures

More information

Table of Contents. Early Identification Chart Biometric Screening Comprehensive Cardiovascular Disease Risk Assessment...

Table of Contents. Early Identification Chart Biometric Screening Comprehensive Cardiovascular Disease Risk Assessment... Public Safety Table of Contents Early Identification Chart... 1 Biometric Screening... 2 Comprehensive Cardiovascular Disease Risk Assessment.... 2 Recommended after Comprehensive Cardiovascular Disease

More information

ALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic

ALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic 1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker

More information

Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway

Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by

More information

Coronary heart disease and stroke

Coronary heart disease and stroke 4 Coronary heart disease and stroke Overview of cardiovascular disease Cardiovascular disease (CVD), also called circulatory disease, describes a group of diseases which are caused by blockage or rupture

More information

Understanding the metabolic syndrome

Understanding the metabolic syndrome Understanding the metabolic syndrome Understanding the metabolic system Metabolic syndrome is the clustering together of a number of risk factors for heart disease, stroke and diabetes. Having one of these

More information

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain

More information

To reduce the risk of cardiovascular disease and diabetes among Oklahoma state employees.

To reduce the risk of cardiovascular disease and diabetes among Oklahoma state employees. E Nancy A. Haller, MPH, CHES, Manager, State Wellness Program M PLOYEES To reduce the risk of cardiovascular disease and diabetes among Oklahoma state employees. To suspend or decrease the rising costs

More information

PREVER STUDY. What we learned with the PREVER-PREVENTION Trial? Dr. Sandra C. Fuchs. Professor at Universidade Federal of Rio Grande do Sul, Brazil

PREVER STUDY. What we learned with the PREVER-PREVENTION Trial? Dr. Sandra C. Fuchs. Professor at Universidade Federal of Rio Grande do Sul, Brazil 11 PREVER STUDY What we learned with the PREVER-PREVENTION Trial? Dr. Sandra C. Fuchs Professor at Universidade Federal of Rio Grande do Sul, Brazil Financial Support: PREVER investigators: Sandra C. FUCHS,

More information

CONTRIBUTING FACTORS FOR STROKE:

CONTRIBUTING FACTORS FOR STROKE: CONTRIBUTING FACTORS FOR STROKE: HYPERTENSION AND HYPERCHOLESTEROLEMIA Melissa R. Stephens, MD, FAAFP Associate Professor of Clinical Sciences William Carey University College of Osteopathic Medicine LEARNING

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Primary prevention of CVD Potential output:

More information

Stroke secondary prevention. Gill Cluckie Stroke Nurse Consultant St. George s Hospital

Stroke secondary prevention. Gill Cluckie Stroke Nurse Consultant St. George s Hospital Stroke secondary prevention Gill Cluckie Stroke Nurse Consultant St. George s Hospital Stroke recurrence The risk of recurrent stroke is greatest after first stroke 2 3% of survivors of a first stroke

More information